Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Solid Biosciences (Nasdaq: SLDB) granted 17,600 restricted stock units (RSUs) to one newly hired employee on March 2, 2026. The RSUs vest in four equal annual installments on each one-year anniversary through the fourth anniversary and are subject to continued service.

The award was made under the company’s 2024 Inducement Stock Incentive Plan as an inducement in accordance with Nasdaq Listing Rule 5635(c)(4).

Key Figures

Inducement RSUs granted: 17,600 RSUs Vesting schedule: 4 equal installments Current share price: $6.21 +3 more

6 metrics

Inducement RSUs granted 17,600 RSUs Grant to one newly hired employee under 2024 Inducement Stock Incentive Plan

Vesting schedule 4 equal installments Annual vesting on each one-year anniversary of the grant date

Current share price $6.21 Price before inducement grant announcement

52-week high $7.37 Pre-news 52-week high level

52-week low $2.41 Pre-news 52-week low level

Market cap $490,055,403 Equity value before this filing-related news

Market Reality Check

Price: $6.20 Vol: Volume 907,952 vs 20-day ...

normal vol

$6.20 Last Close

Volume Volume 907,952 vs 20-day average 1,240,113 (relative volume 0.73) ahead of this filing-related news. normal

Technical Shares traded above the 200-day MA, with price at 6.21 vs 200-day MA of 5.43 before the announcement.

Peers on Argus

SLDB was down 1.27% while peers showed mixed moves: AURA up 0.51%, DMAC down 1.7...

SLDB was down 1.27% while peers showed mixed moves: AURA up 0.51%, DMAC down 1.73%, FULC down 3.46%, LXRX down 1.67%, ALMS down 0.10%, indicating stock-specific trading rather than a uniform sector move.

Historical Context

5 past events · Latest: Feb 09 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Feb 09	FDA meeting feedback	Positive	+5.2%	Positive Type C FDA feedback and Phase 3 IMPACT DUCHENNE trial alignment for SGT-003.
Feb 06	Conference presentation	Positive	+4.7%	Announcement of CEO presentation at Guggenheim Emerging Outlook Biotech Summit 2026.
Jan 13	Pipeline outlook	Positive	+12.6%	2026 outlook highlighting neuromuscular and cardiac pipeline momentum and AAV-SLB101 access.
Jan 12	Orphan designation	Positive	-1.5%	FDA Orphan Drug designation and existing Fast Track and Rare Pediatric Disease status for SGT-212.
Jan 12	First-patient dosed	Positive	-0.9%	First participant dosed in Phase 1b FALCON trial for SGT-212 dual-route gene therapy.

Pattern Detected

Recent company-specific news, especially clinical and regulatory milestones, often coincided with positive price reactions, though two January updates on SGT-212 drew modest negative moves despite positive clinical tone.

Recent Company History

In the past few months, Solid Biosciences has reported multiple pipeline and regulatory milestones. On Jan 13, a 2026 outlook highlighted neuromuscular and cardiac programs and over 50 AAV‑SLB101 agreements, with a 12.6% gain. Earlier in January, FDA Orphan Drug designation and first dosing in the FALCON trial for SGT‑212 saw small negative moves. February brought a Guggenheim summit presentation and positive FDA Type C feedback for SGT‑003’s Phase 3 IMPACT DUCHENNE trial, with 36 Phase 1/2 participants dosed and stock up 4.65% and 5.21%, respectively. Today’s RSU inducement grant fits routine corporate activity rather than a clinical inflection.

Market Pulse Summary

This announcement details a routine equity compensation grant of 17,600 RSUs to a new employee under...

Analysis

This announcement details a routine equity compensation grant of 17,600 RSUs to a new employee under Solid Biosciences’ 2024 inducement plan, structured to vest over four years and subject to continued service. It follows a series of clinically focused updates, including FDA feedback for SGT‑003 and progress across neuromuscular and cardiac programs. Investors may monitor how ongoing RSU grants, insider Form 4 activity, and future clinical milestones interact with the existing $490,055,403 market valuation and recent price history.

Key Terms

restricted stock units, rsus, nasdaq listing rule 5635(c)(4), inducement stock incentive plan

4 terms

restricted stock units financial

"announced grants of 17,600 restricted stock units (“RSUs”) to one newly hired"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

rsus financial

"announced grants of 17,600 restricted stock units (“RSUs”) to one newly hired"

RSUs, or restricted stock units, are a form of company shares given to employees as part of their compensation. They are typically awarded with certain restrictions, such as a waiting period before they can be fully owned or sold, similar to earning a gift that becomes fully yours over time. For investors, RSUs can impact a company's stock offerings and reflect how much the company relies on stock-based incentives to attract and retain talent.

nasdaq listing rule 5635(c)(4) regulatory

"with the Company in accordance with Nasdaq Listing Rule 5635(c)(4)."

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

inducement stock incentive plan financial

"pursuant to the Company’s 2024 Inducement Stock Incentive Plan and was made as"

An inducement stock incentive plan is a program that gives newly hired employees or executives shares or stock-based awards as a reward for joining a company and to encourage them to stay and perform. For investors, it matters because these grants can dilute existing shareholders, increase reported compensation costs, and signal how a company is investing in talent—similar to a signing bonus mixed with a stake in the business.

AI-generated analysis. Not financial advice.

CHARLESTOWN, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced grants of 17,600 restricted stock units (“RSUs”) to one newly hired employee.

The RSUs vest in four equal installments on each one-year anniversary of the grant date until the fourth anniversary of the grant date. Vesting of the equity awards is subject to the applicable employee’s continued service with the Company through each applicable vesting date.

This grant was made pursuant to the Company’s 2024 Inducement Stock Incentive Plan and was made as an inducement material to the employee’s acceptance of employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).

About Solid Biosciences
Solid Biosciences is a precision genetic medicine company focused on advancing a portfolio of gene therapy candidates targeting rare neuromuscular and cardiac diseases, including SGT-003 for Duchenne muscular dystrophy (Duchenne), SGT-212 for Friedreich’s ataxia (FA), SGT-501 for catecholaminergic polymorphic ventricular tachycardia (CPVT), SGT-601 for TNNT2-mediated dilated cardiomyopathy and additional fatal, genetic cardiac diseases. The Company is also focused on developing innovative libraries of genetic regulators and other enabling technologies with promising potential to significantly impact gene therapy delivery cross-industry. Solid is advancing its diverse pipeline and delivery platform in the pursuit of uniting experts in science, technology, disease management, and care. Patient-focused and founded by those directly impacted by Duchenne, Solid’s mission is to improve the daily lives of patients living with devastating rare diseases. For more information, please visit www.solidbio.com.

Solid Biosciences Investor Contact:
Nicole Anderson
Director, Investor Relations and Corporate Communications
Solid Biosciences Inc.
investors@solidbio.com

Media Contact:
Glenn Silver
FINN Partners
glenn.silver@finnpartners.com

FAQ

What did Solid Biosciences (SLDB) announce on March 2, 2026?

They announced a grant of restricted stock units to a new hire to induce employment. According to the company, 17,600 RSUs were granted under the 2024 Inducement Stock Incentive Plan with four-year annual vesting tied to continued service.

How many RSUs did SLDB grant and who received them?

Solid Biosciences granted a total of 17,600 restricted stock units to one newly hired employee. According to the company, the award was an inducement grant made as material consideration for the employee’s acceptance of employment.

What is the vesting schedule for the 17,600 RSUs granted by SLDB?

The RSUs vest in four equal installments on each one-year anniversary of the grant date. According to the company, vesting is contingent on the employee’s continued service through each applicable vesting date until the fourth anniversary.

Under which plan and Nasdaq rule were the SLDB inducement grants made?

The grant was made under the company’s 2024 Inducement Stock Incentive Plan and cited Nasdaq Listing Rule 5635(c)(4). According to the company, the grant qualifies as an inducement material to the employee’s acceptance of employment.

Does the SLDB press release state the shareholder dilution impact of the 17,600 RSU grant?

The company did not disclose a dilution percentage or share-count impact for the RSU grant in the announcement. According to the company, only the grant size, vesting schedule, and plan authority were specified.